AGL 40.01 Decreased By ▼ -0.01 (-0.02%)
AIRLINK 187.98 Increased By ▲ 9.91 (5.57%)
BOP 10.12 Increased By ▲ 0.16 (1.61%)
CNERGY 7.11 Increased By ▲ 0.17 (2.45%)
DCL 10.15 Increased By ▲ 0.06 (0.59%)
DFML 41.57 No Change ▼ 0.00 (0%)
DGKC 107.91 Increased By ▲ 1.02 (0.95%)
FCCL 39.00 Decreased By ▼ -0.03 (-0.08%)
FFBL 82.02 Increased By ▲ 0.13 (0.16%)
FFL 14.90 Increased By ▲ 1.20 (8.76%)
HUBC 119.46 Increased By ▲ 0.21 (0.18%)
HUMNL 14.05 Increased By ▲ 0.05 (0.36%)
KEL 6.40 Increased By ▲ 0.49 (8.29%)
KOSM 8.07 Increased By ▲ 0.01 (0.12%)
MLCF 49.47 Increased By ▲ 1.37 (2.85%)
NBP 73.66 Increased By ▲ 0.83 (1.14%)
OGDC 204.85 Increased By ▲ 11.09 (5.72%)
PAEL 33.56 Increased By ▲ 1.41 (4.39%)
PIBTL 8.07 Increased By ▲ 0.05 (0.62%)
PPL 185.41 Increased By ▲ 11.34 (6.51%)
PRL 33.61 Increased By ▲ 1.01 (3.1%)
PTC 27.39 Increased By ▲ 2.12 (8.39%)
SEARL 119.82 Decreased By ▼ -5.14 (-4.11%)
TELE 9.69 Increased By ▲ 0.27 (2.87%)
TOMCL 35.30 Decreased By ▼ -0.09 (-0.25%)
TPLP 12.25 Increased By ▲ 0.63 (5.42%)
TREET 20.26 Increased By ▲ 1.84 (9.99%)
TRG 60.78 Increased By ▲ 0.29 (0.48%)
UNITY 37.99 Decreased By ▼ -0.22 (-0.58%)
WTL 1.65 Decreased By ▼ -0.01 (-0.6%)
BR100 11,773 Increased By 249.7 (2.17%)
BR30 36,595 Increased By 1045.2 (2.94%)
KSE100 110,810 Increased By 1913.6 (1.76%)
KSE30 34,429 Increased By 620.5 (1.84%)
Business & Finance

Pakistan’s listed pharma sector sees earnings go down 42% YoY in 2023

  • Decline attributed to decrease in gross margin, higher finance cost, says brokerage house
Published March 29, 2024

Earnings of Pakistan’s listed pharmaceutical sector were down 42% YoY to Rs7.9 billion in calendar year 2023, a report from brokerage house Topline Securities stated on Friday.

“This decline is primarily attributed to decrease in gross margins and increase in finance cost,” it added.

The report said despite higher revenue (up 17%) that clocked in at Rs274.5 billion in 2023, mainly on account of increase in drug prices, companies were “unable to sustain gross margins”.

“To recall, in May-2023, the government allowed one-time dispensation, enabling pharmaceutical companies to increase their existing Maximum Retail Price (MRPs) of essential drugs equal to 70% increase in CPI (with a cap of 14%) and MRP of all other non essential up-to increase in CPI (with a cap of 20%) to mitigate the impact of rupee devaluation,” added Topline Securities.

 Source: Topline Securities
Source: Topline Securities

 Source: Topline Securities
Source: Topline Securities

Regulate quality of medicines, not prices, top Pharma Bureau official advises govt

“Despite the rise in prices, companies were unable to sustain gross margins, with the gross profit margin falling to 26% in 2023 from 30% in 2022.”

The report added that a 20% devaluation of the rupee against the US dollar, average inflation of 31%, and the significant increase in finance costs rising by 55% to Rs7.7 billion in 2023 took their toll on earnings.

“Selling and administrative expenses increased by 20% and 17%, respectively, in 2023, which is in line with inflation trend.”

Shortage continues unabated: Need for promoting local production of insulin stressed

The report added that recently in February 2024, the government has approved deregulation of non-essential drug prices which Topline believes will improve the margins of pharmaceutical companies, especially those with a higher mix of non-essential categories.

“They will be able to increase their prices in line with the increase in costs, rather than being subject to any cap on pricing.”

Also read:

Comments

Comments are closed.

Mustafa Mar 29, 2024 01:29pm
DRAP is killing the pharma sector by imposing price restrictions.. restrictions are good if dollar and cost remains at same place ..
thumb_up Recommended (0)
Az_Iz Mar 29, 2024 04:52pm
At least, price increases in line with inflation should be easily allowed.
thumb_up Recommended (0)